

Testosterone Products
Effective 09/01/2022

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input checked="" type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
Exchange	Phone: 855-582-2022	Fax: 855-245-2134	
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Prescriptions that meet the initial step therapy requirements will adjudicate automatically at the point of sale. If the prescription does not meet the initial step therapy requirements, the prescription will deny with a message indicating that prior authorization (PA) is required. Refer to the criteria below and submit a PA request for the members who do not meet the initial step therapy requirements at the point of sale.

Initial Step-Therapy Requirements:

First-Line: Medications listed on first-line are covered without prior-authorization.

Second-Line: Second-line medications will pay if the member has filled at least two different first-line medications or a second-line medication within the past 180 days.

Coverage Guidelines

If a member does not meet the initial step therapy requirements, then approval of a second-line medication will be granted if the member has had a documented inadequate response or side effect to at least two different 1st-line testosterone products **OR** the member has documented clinical rationale to avoid therapy with all first-line agents.

FIRST-LINE	SECOND-LINE
Testosterone enanthate injection	Androderm patch 2mg/24hr and 4mg/24hr
Testosterone cypionate injection	Testosterone topical solution 30 mg/act (<i>compare to Axiron solution</i>)
Testosterone topical gel 1% (<i>compare to AndroGel or Testim</i>)	Testosterone topical gel 1.62% (<i>compare to AndroGel Pump 1.62%</i>)
Testosterone topical gel pump 1% (<i>compare to Vogelxo</i>)	Testosterone topical 1.62% (<i>compare to AndroGel topical 1.62%</i>)
Testosterone topical gel 2% (<i>compare to Fortesta Gel</i>)	Jatenzo (testosterone undecanoate)



FIRST-LINE	SECOND-LINE
	Tlando (testosterone undecanoate)

NOTE: Testopel is covered on the Medical Benefit only. Please refer to the Medical Specialty Drug list criteria.

References

1. Testim (testosterone) [prescribing information]. Malvern, PA: Endo Pharmaceuticals; April 2018.
2. AndroGel 1% (testosterone) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2015.
3. AndroGel 1.62% (testosterone) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2019
4. Axiron (testosterone) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; February 2017.
5. AndroGel 1.62% (testosterone) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2016.
6. Testosterone gel [prescribing information]. Baudette, MN: Ani Pharmaceuticals, Inc; October 2016.
7. Androderm (testosterone) transdermal system [prescribing information]. Irvine, CA: Allergan USA, Inc; October 2016.
8. 38. Fortesta (testosterone) gel [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; July 2017.
9. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.[PubMed 20525905]
10. Therapeutic activity of testosterone in metastatic breast cancer Anticancer Res. 2014 Mar;34(3):1287-90.
11. Hormone therapy for transgender patients: Journal List Transl Androl Urolv.5(6); 2016 Dec PMC518222
12. Testosterone Therapy Improves the First Year Height Velocity in Adolescent Boys with Constitutional Delay of Growth and Puberty: Int J Endocrinol Metab. 2017 Apr; 15(2): e42311.

Review History

09/18/2017: Reviewed

09/24/2018: Reviewed

01/22/2019: Removed clinical rationale from criteria. Only requirement is trials of other 1st line or 2nd line medications.

03/18/2020: Updated (added Jatenzo to 2nd line agent) (effective 6/1/20)

05/19/2021: Updated and Reviewed; Second line agents updated as generic formulations are now available for AndroGel Pump 1.62% and AndroGel topical 1.62%; generic testosterone 1.62% (compare to AndroGel) replaced AndroGel 1.62%. Effective 08/01/2021.

07/20/2022: Updated and Reviewed for July P&T; Added new formulations Tlando as a second line agent. Effective 09/01/2022

09/21/2022: Reviewed and updated for Sept P&T. Separated out Comm/Exch vs. MHEffective 1/1/2023

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.